QuickView: Prophylactic potential
GeoVax continues to work with the HIV Vaccine Trials Network (HVTN) to progress development of its lead GOVX-B11 prophylactic HIV vaccine. To date HVTN has conducted both Phase I and most recently Phase IIa development at an estimated cost of $10m, supported by US NIH funding. A planning meeting with HVTN recently took place and continued collaboration, in the absence of alternative funding, will be key to securing the future development of GOVX-B11.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.